{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=21",
    "query": {
      "intervention": "Advanced therapy",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 6313,
    "total_pages": 632,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T06:54:01.289Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02335944",
      "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Capmatinib",
          "type": "DRUG"
        },
        {
          "name": "Nazartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2015-01-13",
      "completion_date": "2020-11-10",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02335944"
    },
    {
      "nct_id": "NCT00604721",
      "title": "Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "selumetinib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2007-11",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-28",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00604721"
    },
    {
      "nct_id": "NCT03815058",
      "title": "A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma"
      ],
      "interventions": [
        {
          "name": "Autogene cevumeran",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2018-12-21",
      "completion_date": "2025-01-21",
      "has_results": true,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 17,
      "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815058"
    },
    {
      "nct_id": "NCT05609578",
      "title": "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced NSCLC",
        "Metastatic Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Adagrasib oral dose of 400 mg twice daily tablets",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Chemotherapy: Pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin/Carboplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2022-11-22",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 59,
      "location_summary": "Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609578"
    },
    {
      "nct_id": "NCT00000678",
      "title": "Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Zalcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 320,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-14",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Miami, Florida • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000678"
    },
    {
      "nct_id": "NCT04393285",
      "title": "Abemaciclib and Letrozole to Treat Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 53,
      "start_date": "2020-10-10",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 29,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Greenwich",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04393285"
    },
    {
      "nct_id": "NCT04751370",
      "title": "Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Rectal Adenocarcinoma",
        "Stage II Rectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Sigmoidoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Mesorectal Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-02-08",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 213,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04751370"
    },
    {
      "nct_id": "NCT00022529",
      "title": "BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "BMS-214662",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2001-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022529"
    },
    {
      "nct_id": "NCT06951672",
      "title": "AMEND TS Early Feasibility Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Symptomatic Functional MR 3 or Greater"
      ],
      "interventions": [
        {
          "name": "This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Valcare Medical Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-09-11",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06951672"
    },
    {
      "nct_id": "NCT01709292",
      "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Vemurafenib (All Groups)",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib (Post Surgery) - Group A + C",
          "type": "DRUG"
        },
        {
          "name": "Post Surgery - Group B",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-11-07",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-11-14T06:54:01.289Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709292"
    }
  ]
}